摘要
INTRODUCTION Currently, the recommended therapy to control refractory status epilepticus （RSE） is intravenous （IV） anesthetics, such as midazolam, propofol, barbiturates, and so on. However, 15%-26% of RSE cases still cannot be terminated.
INTRODUCTION Currently, the recommended therapy to control refractory status epilepticus （RSE） is intravenous （IV） anesthetics, such as midazolam, propofol, barbiturates, and so on. However, 15%-26% of RSE cases still cannot be terminated.
基金
This work is supported by grants from the National Natural Science Foundation of China （No. 81441037）, the National Key Department of Neurology funded by the Chinese Health and Family Planning Committee, and National Key Department of Critical-care medicine funded by the Chinese Health and Family Planning Committee.
